| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/MED.2610050405 |
| P698 | PubMed publication ID | 2999531 |
| P2093 | author name string | Patchett AA | |
| Wyvratt MJ | |||
| P2860 | cites work | The chemistry of enalapril | Q40076212 |
| Studies on angiotensin-converting enzyme inhibitors. I. Syntheses and angiotensinconverting enzyme inhibitory activity of 2-(3-mercaptopropionyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives | Q42246497 | ||
| Studies on angiotensin converting enzyme inhibitors. II. Syntheses and angiotensin converting enzyme inhibitory activities of carboxyethylcarbamoyl-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives | Q42246850 | ||
| RHC 3659: a new orally active angiotensin converting enzyme inhibitor in normal volunteers | Q43241278 | ||
| New sulfhydryl compounds with potent antihypertensive activities | Q46606977 | ||
| Phenacein - an angiotensin-converting enzyme inhibitor produced by a streptomycete. I. Taxonomy, fermentation and biological properties | Q46616080 | ||
| Isolation and characterization of ancovenin,a new inhibitor of angiotensin I converting enzyme,produced by Actinomycetes | Q70175735 | ||
| Arphamenines A and B, new inhibitors of aminopeptidase B, produced by bacteria | Q71145255 | ||
| The structure of arphamenines A and B | Q71145258 | ||
| Discovery, purification and characterization of the angiotensin converting enzyme inhibitor, L-681,176, produced by Streptomyces sp. MA 5143a | Q72736175 | ||
| Novel microbial inhibitors of angiotensin-converting enzyme. Aspergillomarasmines A and B. | Q105004861 | ||
| P433 | issue | 4 | |
| P304 | page(s) | 483-531 | |
| P577 | publication date | 1985-10-01 | |
| P1433 | published in | Medicinal Research Reviews | Q2436033 |
| P1476 | title | Recent developments in the design of angiotensin-converting enzyme inhibitors | |
| P478 | volume | 5 |
| Q33867966 | A short and efficient synthesis of valsartan via a Negishi reaction |
| Q43773521 | A unique geometry of the active site of angiotensin-converting enzyme consistent with structure-activity studies |
| Q38138420 | ACE inhibitors. A safe option for hypertension and congestive heart failure |
| Q46655081 | Accurate aqueous proton dissociation constants calculations for selected angiotensin-converting enzyme inhibitors. |
| Q37977360 | Angiotensin converting enzyme inhibitors and moderate hypertension |
| Q38031523 | Angiotensin converting enzyme inhibitors: comparative structure, pharmacokinetics, and pharmacodynamics |
| Q38695141 | Angiotensin converting enzyme inhibitors: differences and advantages for first line therapy in hypertension |
| Q41364436 | Angiotensin-converting enzyme (ACE) inhibitor transport in human intestinal epithelial (Caco-2) cells |
| Q34236623 | Angiotensin-converting enzyme inhibitors |
| Q35593485 | Bioactive peptides and proteins |
| Q85572333 | Biological activities of benzoquinones from Badula barthesia and Embelia angustifolia |
| Q24634179 | Chemical informatics uncovers a new role for moexipril as a novel inhibitor of cAMP phosphodiesterase-4 (PDE4) |
| Q37253693 | Comparative modeling of proteins in the design of novel renin inhibitors |
| Q42068724 | Comparisons in vitro, ex vivo, and in vivo of the actions of seven structurally diverse inhibitors of angiotensin converting enzyme (ACE). |
| Q47449837 | Cyanobacteria Nostoc Punctiforme from Abyssal Benthos of Lake Baikal: Unique Ecology and Metabolic Potential |
| Q44588352 | Determination of a novel angiotensin-AT1 antagonist CR 3210 in biological samples by HPLC. |
| Q46452391 | Diketopiperazine formation, hydrolysis, and epimerization of the new dipeptide angiotensin-converting enzyme inhibitor RS-10085. |
| Q46690655 | Drug-excipient incompatibility studies of the dipeptide angiotensin-converting enzyme inhibitor, moexipril hydrochloride: dry powder vs wet granulation |
| Q35214142 | Dual inhibition of angiotensin-converting enzyme and neutral endopeptidase by the orally active inhibitor mixanpril: a potential therapeutic approach in hypertension |
| Q28342588 | Interaction of angiotensin I-converting enzyme with two potent tricyclic inhibitors |
| Q34775956 | Metallotherapeutics: novel strategies in drug design |
| Q37511145 | Mixed inhibitors of angiotensin-converting enzyme (EC 3.4.15.1) and enkephalinase (EC 3.4.24.11): rational design, properties, and potential cardiovascular applications of glycopril and alatriopril |
| Q48392842 | Mnemogenic effects of injecting RA-octil, a CE-inhibitor derivate, systemically or into the basal forebrain |
| Q30339034 | Molecular recognition: the fragment approach in lead generation. |
| Q46276123 | New photoaffinity labelled agonists of bradykinin |
| Q30845584 | Novel peptidomimics as angiotensin-converting enzyme inhibitors: a combinatorial approach |
| Q39764329 | Peptides and related drugs: a review of their absorption, metabolism, and excretion |
| Q68070156 | Preformulation stability studies of the new dipeptide angiotensin-converting enzyme inhibitor RS-10029 |
| Q34066871 | Progress in rapid screening of Bacillus anthracis lethal factor activity. |
| Q38724355 | Recent advances in pharmaceutical chemistry--angiotensin-converting enzyme inhibitors |
| Q41861130 | Relative lipophilicities and structural-pharmacological considerations of various angiotensin-converting enzyme (ACE) inhibitors |
| Q39706320 | Renin inhibitors. |
| Q38014070 | Specificity of binding with matrix metalloproteinases |
| Q80585450 | Stimulation and oxidative catalytic inactivation of thermolysin by copper.Cys-Gly-His-Lys |
| Q61327189 | Structural characterization and solution rotational isomerism of delapril hydrochloride, a dipeptide angiotensin-converting enzyme inhibitor |
| Q30843863 | Study of the chelating properties of Ge(OH)2 functionality as metal binding group for Zn2+ cation in simplified protease-like environments: a DFT analysis |
| Q38968377 | Synthesis of (2S,3R)-3-amino-2-hydroxydecanoic acid and its enantiomer: a non-proteinogenic amino acid segment of the linear pentapeptide microginin. |
| Q39683623 | Towards non-peptide ANG II AT1 receptor antagonists based on urocanic acid: rational design, synthesis and biological evaluation |
Search more.